Top Markets
Coin of the day
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
Rang in Aktien #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Aktienkurs
$5.34
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$2.59M
Veränderung (1 Tag)
-11.00%
Veränderung (1 Jahr)
313.95%
Land
US
Handel Jupiter Neurosciences, Inc. (JUNS)

Kategorie

Aktien-Split-Historie für Jupiter Neurosciences, Inc. (JUNS)
Die Aktie Jupiter Neurosciences, Inc. (Symbol: JUNS) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 15, 2026 statt.
Eine JUNS-Aktie, die vor dem Aug 15, 2026 gekauft wurde, entspricht heute 0 JUNS-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE